TRPV6 alleles do not influence prostate cancer progression

BMC Cancer

Volumn 9, Issue , 2009, Pages

  Kessler, Thorsten ^a   Wissenbach, Ulrich ^a   Grobholz, Rainer ^a   Flockerzi, Veit ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GENOMIC DNA; RNA; UNCLASSIFIED DRUG; VANILLOID RECEPTOR 6; VANILLOID RECEPTOR 6A; VANILLOID RECEPTOR 6B; CALCIUM CHANNEL; TRPV6 PROTEIN, HUMAN; VANILLOID RECEPTOR;

ADULT; AFRICA; ARTICLE; CANCER INCIDENCE; CANCER STAGING; CONTROLLED STUDY; EXON; GENE EXPRESSION; GENE FREQUENCY; GENE ISOLATION; GENETIC POLYMORPHISM; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; GENOTYPE; GLEASON SCORE; HAPLOTYPE MAP; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SALIVA; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; ADENOCARCINOMA; AGED; ALLELE; CASE CONTROL STUDY; COHORT ANALYSIS; DISEASE COURSE; GENETICS; MIDDLE AGED; PATHOLOGY; PROSTATE TUMOR; RACE;

ADENOCARCINOMA; AGED; ALLELES; CALCIUM CHANNELS; CASE-CONTROL STUDIES; COHORT STUDIES; CONTINENTAL POPULATION GROUPS; DISEASE PROGRESSION; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROSTATIC NEOPLASMS; TRPV CATION CHANNELS;

EID: 71149109947     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-9-380     Document Type: Article

References (28)

1. Heighway J, Betticher DC, Hoban PR, Altermatt HJ, Cowen R. Coamplification in tumors of KRAS2, type 2 inositol 1,4,5 triphosphate receptor gene, and a novel human gene, KRAG. Genomics 1996, 35(1):207-214. 10.1006/geno.1996.0340, 8661122.
2. Sakakura C, Hagiwara A, Fukuda K, Shimomura K, Takagi T, Kin S, Nakase Y, Fujiyama J, Mikoshiba K, Okazaki Y. Possible involvement of inositol 1,4,5-trisphosphate receptor type 3 (IP3R3) in the peritoneal dissemination of gastric cancers. Anticancer Res 2003, 23(5A):3691-3697.
3. Wang XT, Nagaba Y, Cross HS, Wrba F, Zhang L, Guggino SE. The mRNA of L-type calcium channel elevated in colon cancer: protein distribution in normal and cancerous colon. Am J Pathol 2000, 157(5):1549-1562. 1885745, 11073814.
4. Zhang L, Zhou W, Velculescu VE, Kern SE, Hruban RH, Hamilton SR, Vogelstein B, Kinzler KW. Gene expression profiles in normal and cancer cells. Science 1997, 276(5316):1268-1272. 10.1126/science.276.5316.1268, 9157888.
5. Latour I, Louw DF, Beedle AM, Hamid J, Sutherland GR, Zamponi GW. Expression of T-type calcium channel splice variants in human glioma. Glia 2004, 48(2):112-119. 10.1002/glia.20063, 15378657.
6. Tsavaler L, Shapero MH, Morkowski S, Laus R. Trp-p8, a novel prostate-specific gene, is up-regulated in prostate cancer and other malignancies and shares high homology with transient receptor potential calcium channel proteins. Cancer Res 2001, 61(9):3760-3769.
7. Wissenbach U, Niemeyer BA, Fixemer T, Schneidewind A, Trost C, Cavalie A, Reus K, Meese E, Bonkhoff H, Flockerzi V. Expression of CaT-like, a novel calcium-selective channel, correlates with the malignancy of prostate cancer. J Biol Chem 2001, 276(22):19461-19468. 10.1074/jbc.M009895200, 11278579.
8. Zhuang L, Peng JB, Tou L, Takanaga H, Adam RM, Hediger MA, Freeman MR. Calcium-selective ion channel, CaT1, is apically localized in gastrointestinal tract epithelia and is aberrantly expressed in human malignancies. Lab Invest 2002, 82(12):1755-1764.
9. Wissenbach U, Niemeyer B, Himmerkus N, Fixemer T, Bonkhoff H, Flockerzi V. TRPV6 and prostate cancer: cancer growth beyond the prostate correlates with increased TRPV6 Ca2+ channel expression. Biochem Biophys Res Commun 2004, 322(4):1359-1363. 10.1016/j.bbrc.2004.08.042, 15336984.
10. Peng JB, Chen XZ, Berger UV, Vassilev PM, Tsukaguchi H, Brown EM, Hediger MA. Molecular cloning and characterization of a channel-like transporter mediating intestinal calcium absorption. J Biol Chem 1999, 274(32):22739-22746. 10.1074/jbc.274.32.22739, 10428857.
11. Fixemer T, Wissenbach U, Flockerzi V, Bonkhoff H. Expression of the Ca2+-selective cation channel TRPV6 in human prostate cancer: a novel prognostic marker for tumor progression. Oncogene 2003, 22(49):7858-7861. 10.1038/sj.onc.1206895, 14586412.
12. Schwarz EC, Wissenbach U, Niemeyer BA, Strauss B, Philipp SE, Flockerzi V, Hoth M. TRPV6 potentiates calcium-dependent cell proliferation. Cell Calcium 2006, 39(2):163-173. 10.1016/j.ceca.2005.10.006, 16356545.
13. True LD. Surgical pathology examination of the prostate gland. Practice survey by American society of clinical pathologists. Am J Clin Pathol 1994, 102(5):572-579.
14. Epstein JI, Allsbrook WC, Amin MB, Egevad LL. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol 2005, 29(9):1228-1242. 10.1097/01.pas.0000173646.99337.b1, 16096414.
15. Muller D, Hoenderop JG, Merkx GF, van Os CH, Bindels RJ. Gene structure and chromosomal mapping of human epithelial calcium channel. Biochem Biophys Res Commun 2000, 275(1):47-52. 10.1006/bbrc.2000.3227, 10944439.
16. Crawford ED. Epidemiology of prostate cancer. Urology 2003, 62(6 Suppl 1):3-12. 10.1016/j.urology.2003.10.013, 14706503.
17. Thorisson GA, Smith AV, Krishnan L, Stein LD. The International HapMap Project Web site. Genome Res 2005, 15(11):1592-1593. 10.1101/gr.4413105, 1310647, 16251469.
18. Stajich JE, Hahn MW. Disentangling the effects of demography and selection in human history. Mol Biol Evol 2005, 22(1):63-73. 10.1093/molbev/msh252, 15356276.
19. Akey JM, Swanson WJ, Madeoy J, Eberle M, Shriver MD. TRPV6 exhibits unusual patterns of polymorphism and divergence in worldwide populations. Hum Mol Genet 2006, 15(13):2106-2113. 10.1093/hmg/ddl134, 16717058.
20. Rowley KH, Mason MD. The aetiology and pathogenesis of prostate cancer. Clin Oncol (R Coll Radiol) 1997, 9(4):213-218.
21. Lopez-Beltran A, Mikuz G, Luque RJ, Mazzucchelli R, Montironi R. Current practice of Gleason grading of prostate carcinoma. Virchows Arch 2006, 448(2):111-118. 10.1007/s00428-005-0102-4, 16328356.
22. Harnden P, Shelley MD, Coles B, Staffurth J, Mason MD. Should the Gleason grading system for prostate cancer be modified to account for high-grade tertiary components? A systematic review and meta-analysis. Lancet Oncol 2007, 8(5):411-419. 10.1016/S1470-2045(07)70136-5, 17466898.
23. Mandelson MT, Wagner EH, Thompson RS. PSA screening: a public health dilemma. Annu Rev Public Health 1995, 16:283-306. 10.1146/annurev.pu.16.050195.001435, 7543756.
24. Hughes DA, Tang K, Strotmann R, Schoneberg T, Prenen J, Nilius B, Stoneking M. Parallel selection on TRPV6 in human populations. PLoS One 2008, 3(2):e1686. 10.1371/journal.pone.0001686, 2246018, 18301763.
25. Burks DA, Littleton RH. The epidemiology of prostate cancer in black men. Henry Ford Hosp Med J 1992, 40(1-2):89-92.
26. Morton RA. Racial differences in adenocarcinoma of the prostate in North American men. Urology 1994, 44(5):637-645. 10.1016/S0090-4295(94)80196-7, 7526522.
27. Powell IJ. Prostate cancer and African-American men. Oncology (Williston Park) 1997, 11(5):599-605. discussion 606-515 passim.
28. Akey JM, Eberle MA, Rieder MJ, Carlson CS, Shriver MD, Nickerson DA, Kruglyak L. Population history and natural selection shape patterns of genetic variation in 132 genes. PLoS Biol 2004, 2(10):e286. 10.1371/journal.pbio.0020286, 515367, 15361935.